HRP20121074T1 - Derivati kinolina i njihovi farmaceutski sastavi - Google Patents

Derivati kinolina i njihovi farmaceutski sastavi Download PDF

Info

Publication number
HRP20121074T1
HRP20121074T1 HRP20121074TT HRP20121074T HRP20121074T1 HR P20121074 T1 HRP20121074 T1 HR P20121074T1 HR P20121074T T HRP20121074T T HR P20121074TT HR P20121074 T HRP20121074 T HR P20121074T HR P20121074 T1 HRP20121074 T1 HR P20121074T1
Authority
HR
Croatia
Prior art keywords
compound according
hydroxy
indan
ylamino
hydroxyethyl
Prior art date
Application number
HRP20121074TT
Other languages
English (en)
Croatian (hr)
Inventor
Olivier Lohse
Stéphanie MONNIER
Jean-Louis Reber
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0613156A external-priority patent/GB0613156D0/en
Priority claimed from GB0613159A external-priority patent/GB0613159D0/en
Priority claimed from GB0613158A external-priority patent/GB0613158D0/en
Priority claimed from GB0613160A external-priority patent/GB0613160D0/en
Priority claimed from EP06117129A external-priority patent/EP1878722A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20121074T1 publication Critical patent/HRP20121074T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HRP20121074TT 2006-06-30 2007-07-02 Derivati kinolina i njihovi farmaceutski sastavi HRP20121074T1 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0613156A GB0613156D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613159A GB0613159D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613158A GB0613158D0 (en) 2006-06-30 2006-06-30 Organic compounds
GB0613160A GB0613160D0 (en) 2006-06-30 2006-06-30 Organic Compounds
EP06117129A EP1878722A1 (en) 2006-07-13 2006-07-13 Quinolinone derivatives and their pharmaceutical compositions
PCT/EP2007/056632 WO2008000839A1 (en) 2006-06-30 2007-07-02 Quinolinone derivatives and their pharmaceutical compositions

Publications (1)

Publication Number Publication Date
HRP20121074T1 true HRP20121074T1 (hr) 2013-01-31

Family

ID=38610531

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20121074TT HRP20121074T1 (hr) 2006-06-30 2007-07-02 Derivati kinolina i njihovi farmaceutski sastavi

Country Status (28)

Country Link
US (2) US8198450B2 (OSRAM)
EP (1) EP2044025B1 (OSRAM)
JP (1) JP5253392B2 (OSRAM)
KR (1) KR101402398B1 (OSRAM)
CN (1) CN101479245B (OSRAM)
AU (1) AU2007264946B2 (OSRAM)
BR (1) BRPI0713951B8 (OSRAM)
CA (1) CA2654801C (OSRAM)
CY (3) CY1113733T1 (OSRAM)
DK (1) DK2044025T3 (OSRAM)
ES (1) ES2396987T3 (OSRAM)
FI (2) FIC20200047I1 (OSRAM)
FR (2) FR20C1054I1 (OSRAM)
HR (1) HRP20121074T1 (OSRAM)
HU (2) HUS2000043I1 (OSRAM)
IL (1) IL195796A (OSRAM)
LT (2) LTC2044025I2 (OSRAM)
LU (2) LUC00185I2 (OSRAM)
MA (1) MA30540B1 (OSRAM)
MX (1) MX2008016542A (OSRAM)
MY (1) MY150468A (OSRAM)
NO (3) NO341709B1 (OSRAM)
NZ (1) NZ573292A (OSRAM)
PL (1) PL2044025T3 (OSRAM)
PT (1) PT2044025E (OSRAM)
SI (1) SI2044025T1 (OSRAM)
WO (1) WO2008000839A1 (OSRAM)
ZA (1) ZA200809948B (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1860192A1 (en) 1996-09-17 2007-11-28 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
KR20120120453A (ko) 2007-09-05 2012-11-01 화이자 리미티드 Ｎ4-(2,2-다이플루오로-4ｈ-벤조〔1,4〕옥사진-3-온)-6-일〕-5-플루오로-ｎ2-〔3-(메틸아미노카보닐메틸렌옥시)페닐〕2,4-피리미딘다이아민의 지나포에이트 염
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
AU2014229361B2 (en) 2013-03-14 2016-08-04 Novartis Ag Deamorphization of spray-dried formulations via spray-blending
EP3347345B1 (en) 2015-09-29 2019-07-31 Inke, S.A. Mixed solvate of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one l-tartrate
CN110724095B (zh) * 2019-09-12 2023-06-09 上海方予健康医药科技有限公司 一种茚达特罗乙酸盐的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05202301A (ja) * 1991-08-29 1993-08-10 Yamamoto Chem Inc ２−アニリノ−３−メチル−６−（Ｎ−ｎ−ブチル−Ｎ−シクロヘキシルアミノ）フルオランの結晶変態、その製造方法及びこの結晶変態を含有する記録材料
EP0688871A3 (en) * 1994-06-24 1998-07-08 Quest International B.V. Preparation of phytosphingosine derivative
FR2777279B1 (fr) * 1998-04-08 2004-08-13 Hoechst Marion Roussel Inc Nouvelles formes cristallines du 1s-[1alpha(2s*,3r*), 9 alpha] 6,10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl) -9[[(1-isoquinolyl)carbonyl]amino]octohydro-6h-pyridazino [1,2-a][1,2]diazepine-1-carboxamide
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0127430D0 (en) 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
US7417051B2 (en) 2002-04-12 2008-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising betamimetics and a novel anticholinergic
US7250426B2 (en) 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
TWI324150B (en) 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
PE20050211A1 (es) 2003-04-02 2005-04-27 Novartis Ag Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas
CA2521271C (en) 2003-04-04 2011-01-04 Novartis Ag Quinoline-2-one-derivatives for the treatment of airways diseases
JP2005343889A (ja) 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd イミダゾピリジン誘導体
GB0411056D0 (en) * 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0413960D0 (en) 2004-06-22 2004-07-28 Novartis Ag Organic compounds
DK1869049T3 (da) 2005-03-21 2009-05-18 Lilly Co Eli Imidazopyridazinforbindelser
GB0511065D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
EP1910369A1 (en) 2005-07-29 2008-04-16 Astellas Pharma Inc. Fused heterocycles as lck inhibitors

Also Published As

Publication number Publication date
MA30540B1 (fr) 2009-06-01
AU2007264946A1 (en) 2008-01-03
ES2396987T3 (es) 2013-03-01
HUS2000043I1 (hu) 2020-12-28
LUC00188I2 (OSRAM) 2024-07-01
CA2654801A1 (en) 2008-01-03
PL2044025T3 (pl) 2013-02-28
ZA200809948B (en) 2009-05-25
NO2020041I1 (no) 2020-11-23
NO2020044I1 (no) 2020-12-07
HUS2000053I1 (hu) 2020-12-28
BRPI0713951A2 (pt) 2012-12-04
AU2007264946B2 (en) 2011-01-20
FR20C1063I1 (fr) 2021-01-22
BRPI0713951B8 (pt) 2021-05-25
CA2654801C (en) 2014-08-19
KR101402398B1 (ko) 2014-06-03
CN101479245B (zh) 2013-05-22
JP5253392B2 (ja) 2013-07-31
FIC20200047I1 (fi) 2020-11-27
FR20C1054I1 (fr) 2020-12-25
EP2044025A1 (en) 2009-04-08
NZ573292A (en) 2011-03-31
KR20090023651A (ko) 2009-03-05
CY1113733T1 (el) 2016-06-22
CY2020041I1 (el) 2021-03-12
US20090325912A1 (en) 2009-12-31
FIC20200050I1 (fi) 2020-12-16
LTPA2020535I1 (lt) 2020-12-28
CN101479245A (zh) 2009-07-08
HK1127597A1 (en) 2009-10-02
JP2009541455A (ja) 2009-11-26
US8198450B2 (en) 2012-06-12
CY2020038I2 (el) 2021-03-12
SI2044025T1 (sl) 2013-01-31
IL195796A0 (en) 2009-09-01
BRPI0713951B1 (pt) 2019-08-13
LUC00185I2 (OSRAM) 2024-07-01
CY2020041I2 (el) 2021-03-12
DK2044025T3 (da) 2013-01-14
US20120316142A1 (en) 2012-12-13
WO2008000839A1 (en) 2008-01-03
CY2020038I1 (el) 2021-03-12
IL195796A (en) 2016-03-31
MY150468A (en) 2014-01-30
MX2008016542A (es) 2009-01-19
PT2044025E (pt) 2012-12-17
NO20090312L (no) 2009-01-28
LTPA2020538I1 (lt) 2021-01-11
NO341709B1 (no) 2018-01-02
LTC2044025I2 (lt) 2022-10-10
EP2044025B1 (en) 2012-10-03

Similar Documents

Publication Publication Date Title
HRP20121074T1 (hr) Derivati kinolina i njihovi farmaceutski sastavi
HRP20151338T1 (hr) [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze mastocita
HRP20121004T1 (hr) (1-fenil-2-piridin-4-il)etil-esteri benzojeve kiseline kao inhibitori fosfodiesteraze
NZ594589A (en) 3h-imidazo [4, 5 -c] pyridine- 6 -carboxamides as anti- inflammatory agents
JP2011500621A5 (OSRAM)
CN116804007B (zh) 普瑞利伟游离碱半水合物、其制造方法和用途
TNSN07164A1 (en) Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists
WO2008000483A3 (en) Phenol derivatives for the treatment of respiratory diseases
SI2760821T1 (en) A salt salt of an anti-inflammatory substituted cyclobutenedione compound
NZ600790A (en) Combination therapy for copd
JP2011507896A5 (OSRAM)
WO2011017201A3 (en) Dp2 antagonist and uses thereof
CN103717571B8 (zh) 9‑氨基甲基取代的四环素类化合物
WO2012035559A3 (en) Sustained release pharmaceutical compositions comprising pregabalin
WO2007099553A3 (en) 1,3-dioxane carboxylic acids
HRP20171614T1 (hr) Heterociklički spojevi, lijekovi koji sadrže te spojeve, njihova primjena i postupci za njihovu proizvodnju
CA2692191C (en) Use of conjugates of hyaluronic acid in the local treatment of hyperproliferative skin diseases
WO2013188283A8 (en) Topical ophthalmological pharmaceutical composition containing sunitinib
JP2017513824A5 (OSRAM)
EA022018B1 (ru) Кристаллические оксалатные соли диамидного соединения
HRP20192010T1 (hr) Muskarinski antagonisti i njihove kombinacije za liječenje bolesti dišnih puteva kod konja
JP2009541455A5 (OSRAM)
WO2008137809A3 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
MX2012007927A (es) Antagonistas de dp2 y usos del mismo.
HRP20100113T1 (hr) Upotreba pripravaka koji sadrže antagonist kapa-opioidnog receptora, namijenjenih liječenju disocijativnih poremećaja